Filing Details
- Accession Number:
- 0001209191-23-025912
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-04-27 19:03:36
- Reporting Period:
- 2023-04-25
- Accepted Time:
- 2023-04-27 19:03:36
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1679363 | Morphic Holding Inc. | MORF | Pharmaceutical Preparations (2834) | 473878772 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1773184 | Marc Schegerin | C/O Morphic Holding, Inc. 35 Gatehouse Drive, A2 Waltham MA 02451 | Cfo And Coo | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2023-04-25 | 50,000 | $15.00 | 74,136 | No | 4 | M | Direct | |
Common Stock | Disposition | 2023-04-25 | 50,000 | $54.71 | 24,136 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy Common Stock) | Disposition | 2023-04-25 | 50,000 | $0.00 | 50,000 | $15.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
77,268 | 2030-04-05 | No | 4 | M | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person dated June 28, 2022.
- The option vested as to 25% of the total shares on April 6, 2021, and then 1/48 of the total shares vest monthly thereafter, with 100% of the total shares vested and exercisable on April 6, 2024, subject to the reporting person's provision of service to the Issuer on each vesting date.